Payment overview · 2025
General Payments
$288.38
13 reported records · 6 companies
Healthcare provider profile · identity verified
Charanjit Sandhu, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SACRAMENTO, CA · NPI 1275500068
Verified facts
What the public records show
CMS Open Payments records show Charanjit Sandhu, M.D. received $288.38 in general payments during 2025 across 13 reported records.
Dexcom, Inc. accounted for 21.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $62.35 | 21.6% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $55.77 | 19.3% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $55.07 | 19.1% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $50.99 | 17.7% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $46.02 | 16.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.18 | 6.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $288.38 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $62.35 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $55.77 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $50.99 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $46.02 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $46.02 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $46.02 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $31.50 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $31.50 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $23.57 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $23.57 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.18 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.18 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 396 | 102 |
| Losartan Potassium | Losartan Potassium | 394 | 98 |
| Levothyroxine Sodium | Levothyroxine Sodium | 366 | 87 |
| Simvastatin | Simvastatin | 293 | 73 |
| Amlodipine Besylate | Amlodipine Besylate | 271 | 58 |
| Metformin Hcl | Metformin Hcl | 201 | 57 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 156 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 153 | 46 |
| Metoprolol Succinate | Metoprolol Succinate | 152 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 129 | 35 |
| Lisinopril | Lisinopril | 124 | 35 |
| Gabapentin | Gabapentin | 113 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 96 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 91 | 21 |
| Trazodone Hcl | Trazodone Hcl | 85 | 23 |
| Paroxetine Hcl | Paroxetine Hcl | 82 | 17 |
| Famotidine | Famotidine | 81 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 77 | 19 |
| Potassium Chloride | Potassium Chloride | 73 | 22 |
| Omeprazole | Omeprazole | 71 | 25 |
| Fenofibrate | Fenofibrate Nanocrystallized | 68 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 64 | 18 |
| Atenolol | Atenolol | 56 | 16 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 56 | 14 |
| Glimepiride | Glimepiride | 54 | 14 |
| Furosemide | Furosemide | 51 | 22 |
| Temazepam | Temazepam | 49 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 49 | suppressed |
| Carvedilol | Carvedilol | 47 | suppressed |
| Meloxicam | Meloxicam | 47 | 16 |
| Montelukast Sodium | Montelukast Sodium | 47 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 46 | 13 |
| Allopurinol | Allopurinol | 45 | 13 |
| Lovastatin | Lovastatin | 44 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 42 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 42 | 11 |
| Azithromycin | Azithromycin | 41 | 38 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 41 | suppressed |
| Felodipine Er | Felodipine | 40 | 11 |
| Januvia | Sitagliptin Phosphate | 38 | 12 |
| Mirtazapine | Mirtazapine | 38 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 35 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 30 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 28 | suppressed |
| Niacin Er | Niacin | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 17 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 27 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Ezetimibe | Ezetimibe | 26 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 25 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Febuxostat | Febuxostat | 23 | suppressed |
| Spironolactone | Spironolactone | 21 | suppressed |
| Eliquis | Apixaban | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 17 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Alprazolam | Alprazolam | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Indapamide | Indapamide | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $288.38 · 13 records | Dexcom, Inc. | ABRYSVO, COMIRNATY, CREON, Dexcom G6 Transmitter, LINZESS, MOUNJARO, PREVNAR 20, QULIPTA, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, ZEPBOUND | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error